Immunotech Biopharm (HKSE:06978) Capex-to-Revenue : 0.00 (As of Jun. 2024)

Immunotech Biopharm Capex-to-Revenue Chart

Immunotech Biopharm Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Capex-to-Revenue	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Immunotech Biopharm's Capex-to-Revenue

For the Biotechnology subindustry, Immunotech Biopharm's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunotech Biopharm's Capex-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunotech Biopharm's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Immunotech Biopharm's Capex-to-Revenue falls into.

Immunotech Biopharm Capex-to-Revenue Calculation

Immunotech Biopharm's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Immunotech Biopharm's Capex-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunotech Biopharm  (HKSE:06978) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.

Immunotech Biopharm Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Immunotech Biopharm's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunotech Biopharm Business Description